Nimustine | CAS# 42471-28-3 | antineoplastic agent

MedKoo Cat#: 414395 | Name: Nimustine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nimustine is an antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.

Chemical Structure

Nimustine

CAS#42471-28-3

Theoretical Analysis

MedKoo Cat#: 414395

Name: Nimustine

CAS#: 42471-28-3

Chemical Formula: C9H13ClN6O2

Exact Mass: 272.0789

Molecular Weight: 272.69

Elemental Analysis: C, 39.64; H, 4.81; Cl, 13.00; N, 30.82; O, 11.73

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Nimustine; CCRIS2751; CCRIS 2751; CCRIS-2751

IUPAC/Chemical Name

3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-1-(2-chloroethyl)-1-nitrosourea

InChi Key

VFEDRRNHLBGPNN-UHFFFAOYSA-N

InChi Code

InChI=1S/C9H13ClN6O2/c1-6-12-4-7(8(11)14-6)5-13-9(17)16(15-18)3-2-10/h4H,2-3,5H2,1H3,(H,13,17)(H2,11,12,14)

SMILES Code

O=C(NCC1=CN=C(C)N=C1N)N(CCCl)N=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 272.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tani H, Kurita S, Miyamoto R, Sawada H, Fujiwara-Igarashi A, Michishita M, Azakami D, Hasegawa D, Tamura K, Bonkobara M. Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma. J Am Anim Hosp Assoc. 2020 May/Jun;56(3):146. doi: 10.5326/JAAHA-MS-6959. Epub 2020 Mar 17. PMID: 32182105. 2: Endo T, Inoue T, Sugiyama S, Saito R, Tominaga T. Regression of Recurrent Spinal Cord High-Grade Glioma After Convection-Enhanced Delivery of Nimustine Hydrochloride: Case Reports and Literature Review. Oper Neurosurg (Hagerstown). 2020 Apr 1;18(4):451-459. doi: 10.1093/ons/opz172. PMID: 31414134. 3: Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology. 2009;76(3):184-9. doi: 10.1159/000201943. Epub 2009 Feb 13. PMID: 19218824. 4: Shibahara T, Ikuta S, Muragaki Y. Machine-Learning Approach for Modeling Myelosuppression Attributed to Nimustine Hydrochloride. JCO Clin Cancer Inform. 2018 Dec;2:1-21. doi: 10.1200/CCI.17.00022. PMID: 30652567. 5: Agarwal S, Jangir DK, Mehrotra R, Lohani N, Rajeswari MR. A structural insight into major groove directed binding of nitrosourea derivative nimustine with DNA: a spectroscopic study. PLoS One. 2014 Aug 7;9(8):e104115. doi: 10.1371/journal.pone.0104115. PMID: 25101667; PMCID: PMC4125164. 6: Takahashi M, Goto-Koshino Y, Fukushima K, Kanemoto H, Nakashima K, Fujino Y, Ohno K, Endo Y, Tsujimoto H. Phase I dose-escalation study of nimustine in tumor-bearing dogs. J Vet Med Sci. 2014 Jun;76(6):895-9. doi: 10.1292/jvms.13-0345. Epub 2014 Feb 10. PMID: 24521794; PMCID: PMC4108775. 7: Yang DY, Bu XY, Zhou ZL, Yan ZY, Ma CX, Qu MQ, Zhao YW, Kong LF, Wang YW, Luo JC. Enhanced antitumor effects of radiotherapy combined local nimustine delivery rendezvousing with oral temozolomide chemotherapy in glioblastoma patients. J Cancer Res Ther. 2018 Jan;14(1):78-83. doi: 10.4103/jcrt.JCRT_844_17. PMID: 29516964. 8: Lu Z, Ma J, Liu B, Dai C, Xie T, Ma X, Li M, Dong J, Lan Q, Huang Q. Hyperbaric oxygen therapy sensitizes nimustine treatment for glioma in mice. Cancer Med. 2016 Nov;5(11):3147-3155. doi: 10.1002/cam4.851. Epub 2016 Oct 13. PMID: 27734611; PMCID: PMC5119970. 9: Ikuta S, Maruyama T, Nitta M, Muragaki Y. [Nimustine hydrochloride/ranimustine efficacy and safety in glioma]. Nihon Rinsho. 2016 Sep;74 Suppl 7:654-661. Japanese. PMID: 30634829. 10: Weller M, Müller B, Koch R, Bamberg M, Krauseneck P; Neuro-Oncology Working Group of the German Cancer Society. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol. 2003 Sep 1;21(17):3276-84. doi: 10.1200/JCO.2003.03.509. PMID: 12947063.